David Carbone is Professor of Internal Medicine, Director of the James Thoracic Center at the OSUMC and holds the Barbara J. Bonner Chair in Lung Research. He graduated summa cum laude from Amherst College in 1977 and received an MD and a PhD in Molecular Biology and Genetics at Johns Hopkins University in 1985. He then did an Internal Medicine internship and residency at The Johns Hopkins Hospital through 1988 followed by a Medical Oncology fellowship at the National Cancer Institute in Bethesda, MD. In 1991, he was appointed Assistant Professor at the University of Texas Southwestern Medical Center and was promoted to Associate Professor with tenure in 1995.
He was recruited to Vanderbilt University in 1996 where he was promoted to full Professor in 1998. At Vanderbilt, he was Professor of Medicine, Cell Biology, and Cancer Biology, and Director of the Thoracic/Head and Neck Cancer Program. He was also Director and Principal Investigator of the Vanderbilt Specialized Program of Research Excellence (SPORE) in Lung Cancer for 11 years and PI of the Strategic Partnering to Evaluate Cancer Signatures (SPECS) in Lung Cancer UO1 consortium.
He was recruited to the Ohio State University in 2012 to direct the James Thoracic Center. His research interests, grant support and publications have been focused on lung cancer, and specifically proteomic and expression array signature development, lung cancer genetics, cancer immunotherapy, tumor-associated immunosuppression mechanisms and gene therapy. Recent research directions include development of molecular biomarkers to guide patient management and therapy, and molecular profiling of lung cancers and preneoplasias to guide the development of novel therapeutics, especially using mass spectrometry-based proteomics.
He has over 200 peer-reviewed publications, books and review articles, has served on several NCI grant review panels, including the clinical program project parent committee, and has continuous NCI funding since early in his career. He has served on organizing committees for both ASCO and AACR and the Board of Scientific Counselors for the NCI, and is currently Chair of the Lung Biology subcommittee for the Eastern Cooperative Oncology Group and President-Elect of the International Association for the Study of Lung Cancer (IASLC). He is co-PI or Lab PI on 8 current or past ECOG trials, including the large phase III lung cancer trials, and is on the steering committee for two global phase III registrational pharma trials.